Merck still sees ‘compelling’ outlook for Terns leukemia drug

Despite updated study data that suggest Terns’ treatment may be less differentiated, company executives claimed Thursday that ...

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy ...

Merck Advances Terns Deal And Cardiovascular And RSV Growth Options

Merck (NYSE:MRK) reported the expiration of the Hart Scott Rodino waiting period for its pending acquisition of Terns ...

Terns Pharmaceuticals Gets Breakthrough Designation for Leukemia Treatment

Terns Pharmaceuticals said it received a breakthrough therapy designation from U.S. regulators for its leukemia treatment. The Food and Drug Administration granted the designation to TERN-701, which ...
Targeted Oncology

FDA Grants Breakthrough Therapy Designation to TERN-701 in Ph+ CP-CML

FDA designates TERN-701 as breakthrough therapy for heavily pretreated Ph+ CP-CML, as allosteric BCR-ABL inhibitor shows ...
AOL

Why Terns Pharmaceuticals Stock Rocked the Market in March

Terns Pharmaceuticals (NASDAQ: TERN) had a more memorable March than a great many other companies on U.S. stock exchanges. That's largely because it agreed to be bought out by a much larger peer, and ...
Devdiscourse

Merck's Keytruda Surge: A Boost Amid Acquisition Costs

Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors ...